1. Introduction {#sec1}
===============

Neuropsychiatric disorders cause severe human suffering and are becoming a major socioeconomic burden to modern society. The rapid development of noninvasive tools for imaging human brains will improve our understanding of complex brain functions and provide more insight into the pathophysiology of neuropsychiatric disorders. Neuroimaging techniques currently utilized in neuropsychiatric disorders include a variety of modalities, such as ultrasound, X-rays, computed tomography (CT), functional magnetic resonance imaging (fMRI), and nuclear medicine imaging \[[@B1]\].

The interactions between transporters/receptors and neurotransmitters play a key role in the diagnosis and treatment of neuropsychiatric disorders. In contrast with conventional diagnostic imaging procedures, which simply provide anatomical or structural pictures of organs and tissues, nuclear medicine imaging is the only tool to visualize the distribution, density, and activity of neurotransmitters, receptors, or transporters in the brain. Nuclear medicine imaging involves the administration of radioactively labeled tracers, which decay over time by emitting gamma rays that can be detected by a positron emission tomography (PET) or single photon emission computed tomography (SPECT) scanner \[[@B2], [@B3]\]. PET uses coincidence detection in lieu of absorptive collimation to determine the positron-electron annihilation, which produces two 511 keV photons in opposite direction. This partially explains the greater spatial resolution and sensitivity of PET. Radioisotopes used in PET imaging typically have short physical half-life and consequently many of them have to be produced with an on-site cyclotron. Radioisotopes used for labeling PET radiopharmaceuticals include ^11^C, ^13^N, ^15^O, ^18^F, ^64^Cu, ^62^Cu, ^124^I, ^76^Br, ^82^Rb, and ^68^Ga, with ^18^F being the most clinically utilized. SPECT radiotracers typically have longer physical half-life than most PET tracers; thus a central radiopharmaceutical laboratory can prepare radiotracers for delivery to SPECT facilities within a radius of several hundred miles. There are a range of radioisotopes (such as ^99m^Tc, ^201^Tl, ^67^Ga, ^123^I, and ^111^In) that can be used for labeling SPECT radiopharmaceuticals, depending on the specific application. ^99m^Tc is the most used radionuclide for nuclear medicine because it is readily available, relatively inexpensive, and gives lower radiation exposure \[[@B2]--[@B4]\].

A major advantage of nuclear medicine imaging is the extraordinarily high sensitivity: a typical PET scanner can detect between 10^−11 ^mol/L to 10^−12 ^mol/L concentrations, whereas MRI has a sensitivity of around 10^−3 ^mol/L to 10^−5 ^mol/L \[[@B4]\]. Because many molecules relevant to neuropsychiatric disorders are present at concentrations below 10^−8 ^M, nuclear medicine imaging is currently the only available *in vivo* method capable of quantifying subtle cerebral pathophysiological changes that might occur before neurostructural abnormalities take place \[[@B5]\].

Radiotracers must fulfill several criteria to be successful for PET or SPECT imaging: including readily labeled with appropriate radionuclide and the labeled radiotracer being stable *in vivo* and nontoxic; sufficient affinity and high selectivity for the specific receptor combined with low nonspecific binding to brain tissue not containing the receptor of interest; rapid permeation through the blood-brain barrier permitting high access of tracers to receptors, as well as allowing high initial brain uptake and fast clearance of the activity from the brain. A large number of radiotracers have been developed for brain imaging, but most of them were utilized only *in vitro* or in experimental animals and only few have the potentiality in clinical practice. Selective radiotracers are available for the study of dopaminergic, acetylcholinergic, serotonergic, and norepinephrine systems, as well as *β*-amyloid plaques with promising results \[[@B5], [@B6]\].

Dopamine is the most intensely studied monoaminergic neurotransmitter. Dopaminergic neurotransmission plays an important role in regulating several aspects of basic brain function, including motor, behavior, motivation, and working memory, and is involved in the pathogenesis of several psychiatric and neurological disorders. Degeneration of the nigrostriatal dopamine system causes Parkinson\'s disease (PD) and related Parkinsonism. Postsynaptic receptors may be involved in neurodegenerative disorders; they are functionally changed in Parkinsonism. Dopamine is thought to be involved in drug abuse. Most drugs of abuse, with the exception of benzodiazepines, have a direct effect on increasing the dopamine reward cycle in the brain. Abnormalities within the dopamine system in the brain play a major role in the pathophysiology of attention deficit hyperactivity disorder (ADHD). Dopamine receptors also play an important role in schizophrenia and the effect of neuroleptics is through blockage of dopamine D~2~ receptors \[[@B6]\]. Neuroimaging techniques permit us to quantify dopaminergic activity in the living human brain, which has become increasingly part of the assessment and diagnosis of neuropsychiatric disorders. To date, there are numerous PET and SPECT radiotracers available for targeting different steps in the process of dopaminergic neurotransmission. This paper will concentrate on the radiotracers that have been developed for imaging dopaminergic neurons, describe their unique strengths and limitations in the assessment of neuropsychiatric disorders, and suggest future directions in the diagnosis and management of neuropsychiatric disorders.

2. Radiotracers for Imaging Dopaminergic Neurons {#sec2}
================================================

Diagnosis of neurological and psychiatric disorders associated with disturbances of dopaminergic functioning can be challenging, especially in the early stages. The evolution of neuroimaging technique over the past decade has yielded unprecedented information about dopaminergic neurons. PET and SPECT techniques have been successfully employed to visualize the activity of dopamine synthesis, reuptake sites, and receptors ([Table 1](#tab1){ref-type="table"}). The Chemical structure of various radiotracers for the assessment of dopamine system is illustrated on [Figure 1](#fig1){ref-type="fig"}. DOPA decarboxylase activity and dopamine turnover can both be measured with ^18^F-DOPA or ^18^F-FMT PET \[[@B7]\]. ^18^F-DOPA PET was the first neuroimaging technique validated for the assessment of presynaptic dopaminergic integrity. The uptake of ^18^F-DOPA reflects both the density of the axonal terminal plexus and the activity of the striatal aromatic amino acid decarboxylase (AADC), the enzyme responsible for the conversion of ^18^F-DOPA to ^18^F-dopamine. However, AADC is present in the terminals of all monoaminergic neurons, measurements of ^18^F-DOPA uptake into extrastriatal areas provides an index of the density of the serotonergic, norepinephrinergic, and dopaminergic terminals \[[@B8]--[@B10]\].

Dopamine transporter (DAT) is a protein complex located in presynaptic dopaminergic nerve terminals, which serves as the primary means for removing dopamine from the synaptic cleft. The availability of presynaptic DAT can be assessed with various radiotracers, which are typically tropane based \[[@B7], [@B11]\]. Several PET tracers (^11^C-CFT, ^18^F-CFT, ^18^F-FP-CIT, and ^11^C-PE2I) and SPECT tracers such as ^123^I-*β*-CIT (Dopascan), ^123^I-FP-CIT (ioflupane, DaTSCAN), ^123^I-altropane, ^123^I-IPT, ^123^I-PE2I, and ^99m^Tc-TRODAT-1 are now available to measure DAT availability \[[@B8], [@B11]--[@B17]\]. ^123^I-*β*-CIT was the first widely applied SPECT tracer in imaging DAT, however, the lack of specificity is a disadvantage. This radiotracer binds not only to DAT but also to norepinephrine transporter (NET) and serotonin transporter (SERT). Another disadvantage of ^123^I-*β*-CIT is considered not convenient for routine out-patient evaluations since adequate imaging should be performed 20--30 h following the injection \[[@B11]\]. The faster kinetics of ^123^I-FP-CIT is a clear advantage for clinical use, which allows adequate acquisition as early as 3 h following injection \[[@B18]\]. Conversely, ^123^I-altropane SPECT images have been less extensively investigated and are more difficult to quantify owing to rapid wash out from the brain \[[@B19]\]. The technetium based ^99m^Tc-TRODAT-1 has the advantage of being relatively inexpensive and available in kit form. The easy preparation of ^99m^Tc-TRODAT-1 from lyophilized kits could be an ideal agent for daily clinical application \[[@B16]\]. However, its specific signal is lower than the ^123^I-based SPECT tracers. To date, only DaTSCAN (^123^I-FP-CIT) and ^99m^Tc-TRODAT-1 are commercially available in the market and licensed for detecting loss of functional dopaminergic neuron terminals in the striatum.

In the brain, dopamine activates the five known types of dopamine receptors---D~1~, D~2~, D~3~, D~4~, and D~5~. Dopamine receptors belong to the G-protein-coupled superfamily. The dopamine D~1~ and D~5~ receptor subtypes are known as D~1~-like receptors and couple to inhibitory G-proteins, whereas the dopamine D~2~, D~3~, D~4~ receptor subtypes are known as D~2~-like family and couple to stimulatory G-proteins. Only dopamine D~1~ and D~2~ receptors have been imaged in humans. For dopamine D~1~ subtype, the most commonly used radiotracers are ^11^C-SCH23390 and ^11^C-NNC112 \[[@B7]\]. As assessment of D~1~-like receptors has not gained clinical significance; therefore many investigations have focused on the D~2~-like receptor system in the past. Dopamine D~2~ receptors are assessed most commonly with the use of benzamide radiotracers. ^11^C-raclopride, ^18^F-spiperone, and ^18^F-methyl-benperidol have been developed for PET imaging; alternatively, ^123^I-IBZM (^123^I-iodobenzamide), ^123^I-epidrpride, and ^123^I-IBF have been developed for SPECT imaging. ^11^C-raclopride is currently the gold standard PET tracer for dopamine D~2~ receptors. In contrast to ^11^C-raclopride, with a physical half-life of approximately 20 min, ^123^I-IBZM allows shipment over considerable distances since the radiotracer has a longer physical half-life of 13.2 h \[[@B20], [@B21]\]. ^123^I-epidrpride, displaying very high affinity to D~2~/D~3~ receptors, has been exploited for quantification and visualization of low density extrastriatal D~2~/D~3~ receptors \[[@B22]\].

The vesicular monoamine transporter type 2 (VMAT2) is expressed by all monoaminergic neurons and serves to pump monoamines from cytosol into synaptic vesicles thereby protecting the neurotransmitters from catabolism by cytosolic enzymes and packaging them for subsequent exocytotic release \[[@B23]\]. In striatum, more than 95% of VMAT2 is associated with dopaminergic terminals and VAMT2 concentration linearly reflects to the concentration of dopamine in the striatum \[[@B24], [@B25]\]. The most widely used radiotracer is \[^11^C\]dihydrotetrabenazine (DTBZ), which binds specifically and reversibly to VMAT2 and is amenable to quantification of striatal, diencephalic, and brain stem neurons and terminals with PET \[[@B23]\]. The ^18^F-labeled VAMT2 tracer, ^18^F-FP-DTBZ (AV-133), has been developed with the advantage of having a half-life of nearly 2 h, which allows shipment of tracers over considerable distances to PET centers without an on-site cyclotron \[[@B27], [@B26]\].

3. Parkinson\'s Disease and Other Movement Disorders {#sec3}
====================================================

Parkinson\'s disease, the second most common neurodegenerative disorder, is characterized by severe loss of dopamine neurons, resulting in a deficiency of dopamine \[[@B28], [@B29]\]. Clinical diagnosis of Parkinson\'s disease relies on the presence of characteristic motor symptoms, including bradykinesia, rigidity and resting tremors, but the rate of misdiagnosis of Parkinson\'s disease using this method was as high as 24% according to previous studies \[[@B30]--[@B32]\]. Good response to dopaminergic drugs, particularly levodopa, is often used to support the clinical diagnosis of Parkinson\'s disease. However, some patients with pathologically confirmed Parkinson\'s disease have a poor response to levodopa; conversely, some patients with early multiple-system atrophy (MSA) or progressive supranuclear palsy (PSP) have beneficial responses to drug treatment \[[@B33]\]. Since the introduction of *in vivo* molecular imaging techniques, the diagnosis of Parkinson\'s disease became more reliable by assessing dopaminergic and even nondopaminergic systems \[[@B34]\].

Imaging of striatal denervation in Parkinson\'s disease was first reported with ^18^F-DOPA PET and has been extended in imaging studies of DAT and VMAT2 \[[@B11], [@B13], [@B14], [@B39]--[@B41], [@B36], [@B37], [@B38], [@B42], [@B23], [@B35]\]. All these markers demonstrate reduced uptake in the striatum, the location of the presynaptic nigral dopamine terminal projections. More specifically, these imaging studies in Parkinson\'s disease patients have shown the nigral neuron loss is asymmetric, where the putamenal reductions are more profound than those in caudate \[[@B10]\]. Studies with ^18^F-DOPA and DAT tracers indicated a reduction in radiotracer uptake of approximately 50--70% in the putamen in Parkinson\'s disease subjects \[[@B39], [@B36], [@B37], [@B38]\]. In general, all these DAT markers show similar findings in Parkinson\'s disease to those seen with ^18^F-DOPA PET and are able to differentiate early Parkinson\'s disease from normal subjects with a sensitivity of around 90% \[[@B6], [@B43]\]. A multicenter phase III trial conducted at Institute of Nuclear Energy Research (INER) in Taiwan indicated that patients with Parkinson\'s disease were easily distinguished from healthy volunteers with ^99m^Tc-TRODAT-1 SPECT, which had a sensitivity of 97.2% and a specificity of 92.6% (unpublished data).

^18^F-DOPA PET is considered as a standard procedure for evaluating dopaminergic metabolism. However, use of ^18^F-DOPA PET may sometimes overestimate the nigral cell reserve in Parkinson\'s disease, since it may show a better than actual uptake due to compensatory increased activity of dopa decarboxylase that occurs with dopamine cell terminal loss \[[@B11]\]. On the contrary, the striatal uptake of DAT radiotracers in early Parkinson\'s disease may overestimate the reduction in terminal density due to the relative downregulation of DAT in the remaining neurons as a response to nigral neuron loss, a compensatory mechanism that acts to maintain synaptic dopamine levels \[[@B41]\]. Additionally, DAT activity falls with age in healthy subjects, but striatal ^18^F-DOPA uptake does not appear to be age dependent \[[@B8], [@B9], [@B40]\].

The signs and symptoms present in early Parkinson\'s disease can resemble those of many other movement disorders, particularly other forms of parkinsonism such as progressive supranuclear palsy, progressive supranuclear palsy, drug-induced Parkinsonism (DIP), vascular Parkinsonism (VP), dementia with Lewy bodies (DLB), and essential tremor (ET) \[[@B10], [@B44]\]. It is important to discriminate between idiopathic Parkinson\'s disease (IPD) and other neurodegenerative Parkinsonian syndromes because there are marked differences in the prognoses and therapies.

Neuroimaging studies indicate that the pattern of dopaminergic neurons loss in Parkinsonian syndromes is less region-specific than in idiopathic Parkinson\'s disease, the putamen and caudate are more equally effected. Moreover, left and right striatal radiotracer uptake in these disorders is also more symmetric than in idiopathic Parkinson\'s disease \[[@B10]\]. Lu et al. found DAT imaging with ^99m^Tc-TRODAT-1 probably could provide important information to differentiate progressive supranuclear palsy from Parkinson\'s disease. The striatal binding was more symmetrically reduced in patients with progressive supranuclear palsy, in contrast to the greater asymmetric reduction in the Parkinson\'s disease groups \[[@B45]\]. Essential tremor is a condition most commonly misdiagnosed with Parkinson\'s disease; up to 25% of cases are initially diagnosed as having Parkinson\'s disease. DAT imaging using ^123^I-*β*-CIT and ^123^I-FP-CIT SPECT has been successfully proven in differentiating essential tremor from Parkinson\'s disease; subjects with essential tremor have normal levels of striatal uptake. Such studies have found the sensitivity and specificity for clinical diagnosis of distinguishing Parkinson\'s disease from essential tremor to be 95% and 93%, respectively \[[@B46], [@B47]\]. Vascular Parkinsonism is a disorder caused by cerebrovascular disease and accounts for 4.4--12% of all cases of Parkinsonism \[[@B48]\]. Dopaminergic imaging studies may help with the diagnosis of vascular Parkinsonism, although studies have provided conflicting results. Two studies (using ^123^I-*β*-CIT or ^99m^Tc-TRODAT-1 SPECT) found near normal DAT binding in patients with vascular Parkinsonism, differentiating them from patients with Parkinson\'s disease, whereas other studies have found reduced DAT binding in some patients with vascular Parkinsonism \[[@B19], [@B36], [@B49]\]. Dementia with Lewy bodies, characterized by severe nigrostriatal dopaminergic neuron degeneration, is the second most common form of degenerative dementia (after Alzheimer\'s disease, AD). Accurate diagnosis in Alzheimer\'s disease and dementia with Lewy bodies is particularly important in the early stage of the disease for the treatment and management of the patient. ^18^F-DOPA, DAT, and VMAT2 markers can differentiate dementia with Lewy bodies, who display lower striatal binding in the putamen, caudate, and midbrain, from those with Alzheimer\'s disease, who have normal striatal binding similar to those observed in healthy controls. Mean sensitivity of ^123^I-FP-CIT scans for a clinical diagnosis of probable dementia with Lewy bodies was 77.7%, while the mean specificity for excluding non-Lewy body dementia was 90.4%, giving overall diagnostic accuracy of 85.7% \[[@B19], [@B50], [@B51], [@B42]\]. In addition, a DAT study with ^99m^Tc-TRODAT-1 scan in DOPA-responsive dystonia (DRD) patients, a hereditary progressive disorder with sustained response to low-dosage levodopa but entirely different prognosis from Parkinson\'s disease, showed significant higher DAT uptake in patients with DOPA -responsive dystonia than those in patients with young onset Parkinson disease (*P* \< 0.001), suggesting a normal nigrostriatal presynaptic dopaminergic terminal in DOPA -responsive dystonia \[[@B52]\].

Higher diagnostic accuracy in the differential diagnosis of Parkinsonism may be achieved by combining pre- and postsynaptic quantitative information about the dopaminergic system. Previous imaging studies with the most commonly used dopamine D~2~ receptor tracers, ^11^C-raclopride and ^123^I-IBZM, have shown that the uptake of DAT are downregulated in patients with early idiopathic Parkinson\'s disease, but D~2~ receptors are comparable to normal subjects in medicated Parkinson\'s disease patients and may even be mildly increased in unmedicated patients. With the progression of Parkinson\'s disease, striatal D~2~ receptor activity returns to normal or may fall below normal levels \[[@B23]\]. In contrast to Parkinson\'s disease, patients with atypical Parkinsonism like progressive supranuclear palsy or progressive supranuclear palsy typically show reductions in both DAT and D~2~ binding \[[@B7], [@B44], [@B53]\]. [Figure 2](#fig2){ref-type="fig"} illustrates the DAT scans with ^99m^Tc-TRODAT-1 and the D~2~ receptor scans with ^123^I-IBZM of healthy volunteer and patients with Parkinson\'s disease, multiple system atrophy, and progressive supranuclear palsy. However, the small differences in D~2~ binding failed to discriminate between idiopathic Parkinson\'s disease, nonidiopathic Parkinson\'s disease, and healthy control groups, according to a report of a multicenter phase III trial conducted by INER (unpublished data). Nevertheless, the dopamine D~2~ receptor imaging is successfully demonstrated in differentiation of the subtypes of progressive supranuclear palsy: Richardson\'s syndrome (RS) and progressive supranuclear palsy-parkinsonism (PSP-P). Assessment of pre- and postsynaptic dopaminergic activities in Richardson\'s syndrome, PSP-P, or idiopathic Parkinson\'s disease with ^99m^Tc-TRODAT-1 and ^123^I-IBZM images showed that the activities of D~2~ receptor were reduced in Richardson\'s syndrome but not in PSP-P (*P* \< 0.01), which was consistent with the clinical manifestation of PSP-P group with better prognosis and levodopa responsiveness than that of RS patients \[[@B54]\].

Imaging the distribution and density of single molecules in the living brain will give us straightforward information of the genetic linkages among different aspects of Parkinsonism. Genetic studies have identified at least 9 genes with mutation that cause 10% to 15% of Parkinson\'s disease cases \[[@B30]\]. *SNCA*, *Parkin*, *PINK1*, *DJ-1*, *LRRK2,* and *ATP13A2* have been identified to be the causative genes for familial and early onset Parkinson\'s disease (EOPD) \[[@B55]\]. A ^99m^Tc-TRODAT-1 scan revealed that patients with the *PINK1*mutation displayed a rather even, symmetrical reduction of dopamine uptake, whereas patients with late-onset Parkinson\'s disease (LOPD) displayed a dominant decline in dopamine uptake in the putamen \[[@B56]\]. The contribution of genetic variants in *ATP13A2*to Parkinson\'s disease of Taiwanese patients was investigated with ^99m^Tc-TRODAT-1 SPECT, showing that the striatal uptake of patients carrying the variants of G1014S and A746T were similar to that of idiopathic Parkinson\'s disease \[[@B55]\]. In addition, ^99m^Tc-TRODAT-1 SPECT was exploited to examine the DAT activity in Machado-Joseph disease (MJD) patients and gene carriers, showing that the DAT concentration was significantly reduced in patients with Machado-Joseph disease and in asymptomatic gene carriers compared to those of healthy volunteers (*P* \< 0.001) \[[@B57]\].

Molecular imaging is also a major tool for the evaluation of new experimental therapeutic strategies in Parkinson\'s disease. Cell transplantation to replace lost neurons is a recent approach to the treatment of progressive neurodegenerative diseases. Transplantation of human embryonic dopamine neurons into the brains of patients with Parkinson\'s disease has proved beneficial in open clinical trials \[[@B7], [@B58]\]. Several teams of investigators have reported the results from double-blind placebo-controlled trials of human embryonic dopaminergic tissue transplantation for the treatment of Parkinson\'s disease. Evaluations with ^18^F-DOPA scans have shown that significant declines in the motor scores over time after transplantation (*P* \< 0.001), based on the Unified Parkinson Disease Rating Scale (UPDRS), were associated with increases in putamen ^18^F-DOPA uptake at 4 years posttransplantation followups (*P* \< 0.001). Furthermore, posttransplantation changes in putamen PET signals and clinical outcomes were significantly intercorrelated (*P* \< 0.02) \[[@B58], [@B59]\]. Gene therapy may be potentially useful for ameliorating the motor symptoms of Parkinson\'s disease. Several gene therapy studies in humans investigated transductions (with various viral vectors) of glial-derived neurotrophic factor (GDNF), neurturin (NTN), AADC, or glutamic acid decarboxylase (GAD). Brain imaging with ^18^F-DODA or ^18^F-FMT PET has been exploited to evaluate clinical outcomes adjunct to the UPDRS scores \[[@B62], [@B64], [@B65], [@B60]--[@B63]\].

4. Drug Abuse and Addicted Brain {#sec4}
================================

Dopamine is the neurotransmitter that has been classically associated with the reinforcing effects of drug abuse. This notion reflects the fact that most of the drugs of abuse increase extracellular dopamine concentration in limbic regions including nucleus accumbens (NAc). The involvement of dopamine in drug reinforcement is well recognized but its role in drug addiction is much less clear. Imaging studies have provided evidences of how the human brain changes as an individual becomes addicted \[[@B66]--[@B69]\].

Cocaine is considered one of the most reinforcing drug of abuse; therefore, this drug has been extensively investigated the associated reinforcing effects in humans. Cocaine is believed to work by blocking the DAT and thereby increasing the availability of free dopamine within the brain. The relationship between DAT blockage and the reinforcement effects of cocaine abuser has been assessed with ^11^C-cocaine PET, showing that intravenous cocaine at doses commonly abused by human (0.3--0.6 mg/kg) blocked between 60 to 77% of DAT sites in these subjects. Moreover, the magnitude of the self-reported "high" was positively correlated with the degree of DAT occupancy, and at least 47% of the transporters had to be blocked for subjects to perceive cocaine\'s effects \[[@B70]\]. When compared to normal controls, cocaine abusers showed significant decreases in dopamine D~2~ receptor availability that persisted 3-4 months after detoxification. Decreases in dopamine D~2~ receptor availability were associated with decreased metabolism in several regions of the frontal lobes, most markedly in orbito-frontal cortex and cingulate gyri \[[@B71]\]. PET studies with ^11^C-raclopride have consistently shown that subjects with a wide variety of drug addictions (cocaine, heroin, alcohol, and methamphetamine) have significant reductions in dopamine D~2~ receptor availability in the striatum that persist months after protracted detoxification \[[@B68], [@B72], [@B74]--[@B76], [@B73]\].

Since dopamine D~2~ receptors are involved in the response to reinforcing properties of natural as well as drug stimuli, it has been postulated that reduced D~2~ receptor levels in drug-addicted subjects would make them less sensitive to natural reinforcers. Volkow et al. compared the function of the dopamine system of 20 cocaine-dependent subjects with 23 controls using ^11^C-raclopride PET by measuring the relative changes in extracellular dopamine induced by intravenous methylphenidate. Cocaine-dependent subjects showed reduced dopamine release in the striatum and also had a reduced "high" relative to controls, indicating that methylphenidate-induced striatal dopamine increased in cocaine abusers were significantly blunted when compared with those of controls \[[@B66], [@B73]\].

Despite the similarities between cocaine and methylphenidate in their affinity to the DAT, cocaine is much more abused than methylphenidate. Using ^11^C labeled cocaine and methylphenidate for PET imaging, it has been demonstrated that the regional distribution of ^11^C-methylphenidate was identical to that of ^11^C-cocaine and they competed with each other for the same binding site. However, these two drugs differed markedly in their pharmacokinetics. Both drugs entered the brain rapidly after intravenous administration (in less than 10 min) while the rate of clearance of ^11^C-methylphenidate from striatum (90 min) was significantly slower than that of ^11^C-cocaine (20 min). Therefore, it is postulated that the initial uptake of these stimulant drugs into the brain, not their steady-state presence, is necessary for drug-induced reinforcement \[[@B68], [@B77]\].

In addition to differences in bioavailability, the route of administration significantly affects the effects of stimulant drugs presumably via its effects on pharmacokinetics. This is particularly relevant to methylphenidate because it is abused when taken intravenously but rarely so when taken orally. Volkow et al. measured the dopamine changes induced by oral and intravenous administration of methylphenidate that produce equivalent DAT occupancy (about 70%). Even though the dopamine increases were comparable for oral and intravenous (approximately 20% changes in specific binding of ^11^C-raclopride in striatum), oral methylphenidate did not induce significant increases in self-reports of "high." Intravenous administration of methylphenidate leads to fast dopamine changes, whereas oral administration increases dopamine slowly. The failure to observe the "high" with oral methylphenidate is likely to reflect the slower pharmacokinetics \[[@B68], [@B69], [@B78]\].

A view of DAT regulation in cocaine addicts may improve our understanding of clinical aspects of cocaine dependence, including drug-induced carving, dysphoria, and relapse. The DAT levels in the brain of cocaine-dependence were measured by ^99m^Tc-TRODAT-1 SPECT. It has shown that there were significantly higher DAT levels in cocaine-dependent subjects compared to controls for the anterior putamen, posterior putamen, and caudate. DAT levels in these regions were 10%, 17%, and 8% higher in the cocaine dependent subjects compared to controls. This study also showed that ^99m^Tc-TRODAT-1 uptake was negatively correlated with the duration of time since last use of cocaine \[[@B79]\]. Malison et al. examined the striatal DAT levels in 28 cocaine-abusing subjects with ^123^I-*β*-CIT SPECT and found that striatal DAT levels were significantly increased (approximately 20%) in acutely abstinent cocaine-abusing subjects (96 h or less) \[[@B80]\]. Another study using ^123^I-*β*-CIT SPECT also showed approximately a 14% increase in DAT availability in acutely abstinent (3.7 days on average) cocaine subjects compared to controls \[[@B81]\].

Human imaging studies suggest that preexisting differences in dopamine circuits may be one mechanism underlying the variability in responsiveness to drug abuse. In particular, baseline measures of striatal dopamine D~2~ receptors in nonaddicted subjects have been shown to predict subjective responses to the reinforcing effects of intravenous methylphenidate treatment. Individuals describing the experience as pleasant had substantially lower levels of dopamine D~2~ receptors compared with those describing methylphenidate as unpleasant \[[@B66], [@B82]\].

Methadone maintenance treatment has been demonstrated to be effective in reducing or eliminating opioid drug use. Despite its therapeutic effectiveness, relatively little is known about neuronal adaptations in the brains of methadone users. A PET study with ^11^C-CFT has documented reduced DAT availability in patients with prolonged abstinence and with methadone maintenance treatment. Furthermore, the subjects with methadone maintenance treatment showed significant decreases of DAT uptake function in the bilateral putamen in comparison to the prolonged abstinence subjects \[[@B83]\]. Another study examined the differences between opioid-dependent users treated with a very low dose of methadone or undergoing methadone-free abstinence. The striatal DAT availability was significantly reduced in low-dose methadone users (0.78 ± 0.27) and methadone-free abstinence (0.94 ± 0.28) compared to controls (1.16 ± 0.26), which has demonstrated that methadone treatment or abstinence can benefit the recovery of impaired dopamine neurons. Moreover, lower midbrain SERT availability also was noted in methadone maintenance treatment and methadone-free abstinence groups, which implicated deregulation of serotoninergic neurons in opioid abuse \[[@B84]\].

The behavioral and neurobiological effects of tobacco smoking, in which nicotine may play an import role, are similar to those of addictive drugs. The pre- and postsynaptic activity of dopamine neuron was examined in male smokers with ^99m^Tc-TRODAT-1/^123^I-IBZM SPECT. A decrease in DAT availability was found in the striatum of male smokers (*P* \< 0.05), suggesting cigarette smoking may alter central dopamine functions, particularly at the presynaptic sites. Moreover, the total FTND (Fagerström Test for Nicotine Dependence) scores correlated negatively with striatal DAT availability in male smokers, but not with striatal D~2~ bindings \[[@B85]\].

5. Attention Deficit Hyperactivity Disorder {#sec5}
===========================================

Attention deficit hyperactivity disorder (ADHD) is a common disorder of childhood characterized by inattention, excessive motor activity, impulsiveness, and distractibility. It is associated with serious disability in children, adolescents and adults. There is converging evidence that abnormalities within the dopamine system in the brain play a major role in the pathophysiology of ADHD \[[@B87], [@B86], [@B88]\]. Despite extensive investigation of the neuropathophysiology of ADHD by a wide array of methodologies, the mechanism underlying this disorder is still unknown.

Neuroimaging holds promise for unveiling the neurobiological causes of ADHD and provides invaluable information for management of the disease. Ernst et al. investigated the integrity of presynaptic dopaminergic function in children with ADHD through the use of ^18^F-DOPA PET and found a 48% increase in DOPA decarboxylase activation in the right midbrain in ADHD children compared with normal controls \[[@B89]\].

Methylphenidate is considered as a first-line medication for ADHD in children and adults \[[@B90], [@B91]\]. This medicine is very effective for the treatment of ADHD; it is estimated that 60--70% of ADHD subjects have favorable responses. Volkow et al. utilized ^11^C-cocaine and ^11^C-raclopride PET to assess the DAT and dopamine D~2~ receptor occupancy for a given dose of methylphenidate. It has been proven that this drug significantly blocked DAT (60 ± 11%) and increased synaptic dopamine levels (16 ± 8%) reduction in ^11^C-raclopride binding in the striatum \[[@B90]\].

It is widely accepted that the therapeutic effects of methylphenidate are through the blocking of DAT; therefore, it seems appropriate to investigate the DAT availability in patients with ADHD. The first DAT imaging study was conducted in 6 adults with ADHD by using ^123^I-altropane SPECT, showing that the DAT levels in unmedicated patients were approximately 70% higher than those in controls \[[@B92]\]. However, following studies with a variety of DAT markers have shown a much smaller increase even not reaching statistical significance than that found in the first study with ^123^I-altropane \[[@B97], [@B96], [@B93], [@B94], [@B95]\]. Dresel et al. investigated DAT binding in 17 treatment naïve adults with ADHD compared with 10 age- and gender-matched control subjects by using ^99m^Tc-TRODAT-1 SPECT. Patients with ADHD exhibited a significantly increased specific DAT binding in the striatum (average 17%) compared with normal subjects (*P* \< 0.01) \[[@B93]\]. Furthermore, Krause et al. examined DAT binding in an expanded sample of 31 adults with ADHD and 15 control subjects; the earlier findings of greater DAT binding in adults with ADHD was replicated \[[@B86]\]. DAT density has been compared in 9 treatment naïve children with ADHD and 6 normal children using ^123^I-IPT SPECT, showing that mean DAT binding in the basal ganglia was significantly increased with 40% on the left and 51% on the right side compared with the controls \[[@B95]\]. By using ^11^C-altropane PET, a highly selective radiotracer and technically superior imaging modality, Spencer et al. found that the overall DAT binding was increased 28% in adults with ADHD compared with controls \[[@B87]\]. However, the ^123^I-*β*-CIT SPECT study showed no significant difference in striatal density between adult patients with ADHD and normal controls \[[@B97]\]. Furthermore, Hesse et al. found the striatal DAT binding ratio (specific to nondisplaceable binding) was significantly reduced in treatment naïve adults with ADHD by using ^123^I-FP-CIT SPECT (ADHD: 5.18 ± 0.98; control: 6.36 ± 1.34) \[[@B98]\]. The cause of divergent findings might be the clinical heterogeneity of the ADHD phenotype rather than differences in imaging technology, applied tracer type, or outcome measurement method.

It has been shown that methylphenidate lowers DAT availability very effectively in normal subjects and in patients with ADHD. After treatment with methylphenidate (5 mg t.i.d), the specific DAT binding decreased (average 29%) significantly in all patients (*P* \< 0.01), investigated by ^99m^Tc-TRODAT-1 SPECT \[[@B93]\]. Vles et al. examined DAT binding in 6 treatment naïve boys with ADHD (aged 6--10 years), using ^123^I-FP-CIT SPECT. Three months after treatment with methylphenidate, a 28--75% decrease of DAT binding in the striatum was found \[[@B99]\]. Generally nonresponse to methylphenidate is known to occur in approximately 30% of patients with ADHD, which may be caused by lower baseline DAT availability in these patients. Krause et al. assessed the relationship between DAT availability and treatment outcome using ^99m^Tc-TRODAT-1 SPECT. It has shown that ADHD patients with poor response to methylphenidate had a low primary DAT availability, whereas most of patients with high DAT availability exhibited good clinical response to methylphenidate \[[@B100], [@B101]\].

Previous studies have confirmed the reduction of DAT availability by nicotine \[[@B85], [@B102]\]. Patients with ADHD and with a history of nicotine abuse displayed lower DAT availability than nonsmokers with ADHD. DAT seems to be elevated in nonsmoking ADHD patients suffering from the purely inattentive subtype of ADHD as well as in those with the combined or purely hyperactive/impulsive subtype \[[@B88], [@B103]\].

6. Schizophrenia and the Effects of Antipsychotics {#sec6}
==================================================

Schizophrenia is a chronic mental illness characterized by disturbances of thoughts, perceptions, volition, and cognition. Manifestations of the illness are commonly divided into positive (delusions, hallucinations, thought disorganization, paranoia), negative (lack of drive and motivation, alogia, social withdrawal), and cognitive symptoms (poor performance on cognitive tasks involving attention and working memory). Positive symptoms are considered to be a result of the increased subcortical release of dopamine causing greater stimulation of D~2~ receptors. The negative and cognitive symptoms are thought to arise from reduced D~1~ receptor stimulation \[[@B104], [@B105], [@B106]\].

With the advance of brain imaging techniques, direct evidence suggestive of dysregulation of dopaminergic transmission in schizophrenia has emerged. Several lines of study have documented an increase in the striatal accumulation of ^18^F-DOPA or ^11^C-DOPA in patients with schizophrenia, which is consistent with increased activity of DOPA decarboxylase, an enzyme involved in dopamine synthesis \[[@B104], [@B105]\]. More recently, Howes et al. assessed striatal dopaminergic function in patients with prodromal schizophrenia using ^18^F-DOPA PET and found elevated striatal ^18^F-DOPA uptake, which gradually reached the level in those with schizophrenia. In addition, increased striatal ^18^F-DOPA uptake was correlated with the severity of prodromal psychopathologic and neuropsychological impairment \[[@B107]\].

Since the primary target of many antipsychotic drugs is antagonism at striatal D~2~ receptors, Abi-Dargham et al. compared striatal D~2~ receptor availability before and during pharmacologically induced acute dopamine depletion with ^123^I-IBZM SPECT in 18 untreated patients and 18 controls. At baselines, no difference has been found between these 2 groups. However, after depletion of endogenous dopamine, D~2~ receptor availability was significantly higher in patients with schizophrenia compared with controls (*P* \< 0.01). In addition, the study suggests elevated synaptic dopamine is predictive of good treatment response of positive symptoms to antipsychotic drugs \[[@B105]\].

PET studies with ^11^C-SCH2390 or ^11^C-NNC112 in drug naïve schizophrenia patients have reported divergent findings in D~1~ receptor binding and cognitive functioning. Some studies have shown a decrease in prefrontal D~1~ receptor binding \[[@B108]\], whereas others have shown an increase in D~1~ receptor binding \[[@B109]\] or reported no differences between patients and controls \[[@B110]\]. A few have shown a relationship between D~1~ dysfunction and working memory performance in treatment naïve patients. The variability in the results was possibly influenced by parameters of the particular patient populations including duration of illness, symptoms and medications.

Nuclear medicine imaging technique has been widely used for the drug development in recent years. There are several approaches such as microdosing, measurement of *in vivo* receptor occupancy, and biomarkers \[[@B111]\]. Most imaging studies in the past have concentrated on antipsychotics. Several lines of research indicate the efficacy of antipsychotics to be related to their capacity to antagonize dopamine. Brain Imaging with PET or SPECT allows determination of dopamine D~2~ receptor occupancy rate in the human brain during treatment with antipsychotics, which are associated with extrapyramidal symptoms (EPS) of antipsychotic drugs \[[@B112]\]. Farde et al. found that the classical antipsychotics occupied 60--85% of striatal dopamine D~2~ receptor was necessary for treating positive symptoms of schizophrenia, as measured by ^11^C-raclopride PET imaging. However, D~2~ receptor occupancies above 80% were associated with a significantly higher risk of extrapyramidal symptoms \[[@B113], [@B112], [@B114]\].

Several new antipsychotics have been introduced to market with lower affinity for dopamine D~2~ receptors, for which the term "atypical antipsychotics" had been coined. Atypical antipsychotics display with a low or nonexistent propensity of extrapyramidal symptoms as compared to classical neuroleptics \[[@B115]\].

Therapeutic concentrations reported from clinical studies have been confirmed by D~2~ receptor imaging for classical antipsychotics and a number of atypical antipsychotics (i.e., amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, and zotepine). From available studies, the atypical antipsychotics clozapine and quetiapine appear to have the lowest striatal D~2~ receptor occupancy rates and the typical antipsychotic haloperidol has the highest. Risperidone, sertindole, and zotepine hold an intermediate position. The incidence of EPS ranged from none with clozapine, olanzapine, quetiapine, to 80% of patients treated with haloperidol \[[@B118], [@B116], [@B117], [@B119]\]. The effect of DAT on a neuroleptic was examined by ^123^I-FP-CIT SPECT. Mateos and coworkers found in schizophrenic patients 4 weeks of treatment with risperidone did not influence striatal DAT binding ratios significantly \[[@B120]\].

7. Conclusions {#sec7}
==============

With the appropriate radiotracers, neuroimaging enables the visualization of the presynaptic and postsynaptic sites in the dopaminergic system. Imaging these markers provides key insights into the pathophysiology of Parkinson\'s disease and related neurodegenerative diseases and it becomes an important endpoint in clinical trials of potential disease-modifying therapy for Parkinson\'s disease such as gene therapy or cell replacement therapy. The availability of easy-to-apply diagnostic procedures such as metabolic and DAT imaging is encouraging. Nonetheless, it should also be emphasized that these results are no replacement for thorough clinical investigation. Future studies are needed in the development of new radiotracers to target nondopaminergic brain pathways and the glial reaction to disease.

Neuroimaging studies have provided evidences of how the human brain changes as an individual becomes addicted. Although available studies have mostly focused on dopamine, the interaction of dopamine with other neurotransmitters such as GABA, glutamate, and serotonin plays an important role in modulating the magnitude of the dopamine responses to drugs.

At this time, knowledge from DAT imaging studies in patients with ADHD is limited by the use of various radiotracers and small sample size. In the future, measurements of DAT with PET or SPECT should be performed in greater collectives, allowing the assignment to different subtypes of ADHD. Of further interest will be whether the DAT availability has a prognostic value for the treatment response of methylphenidate. Furthermore, since methylphenidate exerts its therapeutic efficacy is through blocking DAT and NET, the role of norepinephrinergic system in the pathophysiology of ADHD will become increasing important as the recently available of NET radiotracers.

The clinically most important contribution from neuroimaging on D~2~ receptor occupancy in patients with schizophrenia is probably the identification of the optimal therapeutic window for antipsychotic drugs. Based on this concept, the striatal D~2~ receptors binding profiles of typical and atypical antipsychotic agents has been determined.

In the future, the role of neuroimaging may become more significant in guiding therapy. Enhancements in image resolution and specific molecular tags will permit accurate diagnoses of a wide range of diseases, based on both structural and molecular changes in the brain. For widespread application, advances in molecular imaging should include the characterization of new radiotracers, application of modeling techniques, standardization and automation of image-processing techniques, and appropriate clinical settings in large multicenter trials. The growing field of neuroimaging is helping nuclear medicine physicians identify pathways into personalized patient care.

The authors are indebted to the research teams of Chang Gung Memorial Hospital, Tri-Service General Hospital, National Cheng Kung University Hospital, and Taipei Veterans General Hospital for carrying out the clinical studies for the neuroimaging agents developed at Institute of Nuclear Energy Research. The development of neuroimaging agents was partially supported by the Grant from National Science Council (NSC99-3111-Y-042A-013).

###### 

Chemical structure of various radiotracers for the assessment of dopamine synthesis, reuptake sites, and receptors.
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![Dopamine transporter (DAT) imaging with ^99m^Tc-TRODAT-1 and dopamine D~2~ receptor imaging with^123^I-IBZM of healthy volunteer and patients with Parkinson\'s disease (PD), multiple-system atrophy (MSA), and progressive supranuclear palsy (PSP). The striatal DAT uptakes were significantly decreased in patients with PD, MSA, and PSP, whereas the dopamine D~2~ receptor uptakes were mildly decreased in patients with PD, MSA, and PSP.](JBB2012-259349.002){#fig2}

###### 

Radiotracers available for targeting different steps in the process of dopaminergic neurotransmission and clinical applications.

  Targeting                                Tracer                                                                                                                                                                                                      Chemical name                                                                                                                                                                                                                                                                                      Clinical studies (references)
  ---------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Dopamine synthesis and turn over         ^18^F-DOPA                                                                                                                                                                                                  L-3,4-dihydroxy-6-\[^18^F\]-fluorophenylalanine                                                                                                                                                                                                                                                    PD \[[@B11], [@B24]--[@B41]\], gene therapy for PD \[[@B58]--[@B62]\], ADHD \[[@B89]\], schizophrenia \[[@B104], [@B107]\]
  ^18^F-FMT                                O-\[^18^F\]-fluoromethyl-D-tyrosine                                                                                                                                                                         Gene therapy for PD \[[@B64], [@B65]\]                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dopamine transporter                     ^11^C-CFT                                                                                                                                                                                                   \[^11^C\]-2*β*-carbomethoxy-3*β*-ltropane                                                                                                                                                                                                                                                          Heroin abuse \[[@B83]\]
  ^11^C-altropane                          2*β*-carbomethoxy-3*β*-(4-fluorophenyl)-N-((E)-3-iodo-prop-2-enyl)tropane                                                                                                                                   ADHD \[[@B87]\]                                                                                                                                                                                                                                                                                    
  ^123^I-*β*-CIT (Dopascan)                \[^123^I\]-(1R)-2-*β*-carbomethoxy-3-*β*-(4-iodophenyl)-tropane                                                                                                                                             PD \[[@B11], [@B24]\], PM \[[@B36]\], PD & ET \[[@B46]\], cocaine abuse \[[@B80], [@B81]\], ADHD \[[@B97]\]                                                                                                                                                                                        
  ^123^I-FP-CIT (DaTSCAN)                  \[^123^I\] N-*ω*-fluoropropyl-2*β*-carbomethoxy-3*β*-(4-iodophenyl) nortropane                                                                                                                              PM \[[@B37]--[@B53]\], PM & ET \[[@B47]\], PD & DLB \[[@B50]\], AD, PD & DLB \[[@B51]\], ADHD \[[@B96]--[@B99]\], schizophrenia \[[@B120]\]                                                                                                                                                        
  ^99m^Tc-TRODAT-1                         \[^99m^Tc\]technetium \[2-\[\[2-\[\[\[3-(4-chlorophenyl)-8-methyl-8-azabicyclo \[3.2.1\]oct-2-yl\]-methyl\](2-mercaptoethyl)amino\]-ethyl\]amino\]ethane-thiolato(3-)-N2,N2′,S2,S2′\]oxo-\[1R-(exo-exo)\]   PD \[[@B41], [@B38]--[@B55]\], MSA \[[@B45]\], PM & VP \[[@B49]\], DRD \[[@B52]\], PSP \[[@B54]\], genetic study of PD \[[@B55], [@B56]\], genetic study of MJD \[[@B57]\], cocaine abuse \[[@B79]\], opiate abuse \[[@B84]\], nicotine dependence \[[@B85], [@B102]\], ADHD \[[@B86]--[@B103]\]   
  ^123^I-altropane                         \[^123^I\]-2*β*-carbomethoxy-3*β*-(4-fluorophenyl)-N-(1-iodoprop-1-en-3-yl) ortropane                                                                                                                       PD \[[@B39]\], ADHD \[[@B92]\]                                                                                                                                                                                                                                                                     
  ^123^I-IPT                               \[^123^I\]-N-(3-iodopropen-2-yl)-2-carbomethoxy-3beta-(4-chlorophenyl) tropane                                                                                                                              ADHD \[[@B95]\]                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dopamine D~1~ receptor                   ^11^C-NNC 112                                                                                                                                                                                               (+)-5-(7-Benzofuranyl)-8-chloro-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine                                                                                                                                                                                                             Schizophrenia \[[@B109]\]
  ^11^C-SCH 23390                          (R)-(+)-8-Chloro-2,3,4,5-tetrahydro-3-\[^11^C\]methyl-5-phenyl-1H-3-benzazepin-7-ol                                                                                                                         Schizophrenia \[[@B108], [@B110]\]                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Dopamine D~2~ receptor                   ^11^C-Raclopride                                                                                                                                                                                            3,5-dichloro-N-{\[(2S)-1-ethylpyrrolidin-2-yl\]methyl}-2-hydroxy-6-\[^11^C\]methoxybenzamide                                                                                                                                                                                                       Drug abuse \[[@B66]--[@B82]\] cocaine abuse \[[@B70], [@B71]\], methamphetamine abuse \[[@B74]\], opiate abuse \[[@B75]\], alcohol dependence \[[@B76]\], ADHD \[[@B78], [@B90]\], antipsychotics \[[@B120], [@B113]--[@B118]\]
  ^123^I-IBZM                              (S)-(-)-3-\[^123^I\]iodo-2-hydroxy-6-methoxy-N-\[(1-ethyl-2-pyrrolidinyl)methyl\]benzamide                                                                                                                  PM \[[@B44], [@B53]\], schizophrenia \[[@B105]\], antipsychotics \[[@B118], [@B116], [@B117]\]                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  vesicular monoamine transporter type-2   ^11^C-DTBZ                                                                                                                                                                                                  (±)-*α*-\[^11^C\]dihydrotetrabenazine                                                                                                                                                                                                                                                              PD \[[@B7], [@B11], [@B24]\]
  ^18^F-FP-DTBZ (AV-133)                   9-\[^18^F\]fluoropropyl-(+)-dihydrotetrabenazine                                                                                                                                                            PD \[[@B27]\], DLB & AD \[[@B42]\]                                                                                                                                                                                                                                                                 

Abbreviations: Parkinson\'s disease (PD), Parkinsonism (PM), multiple-system atrophy (MSA), progressive supranuclear palsy (PSP), essential tremor (ET), vascular Parkinsonism (VP), Machado-Joseph disease (MJD), DOPA-responsive dystonia (DRD), dementia with Lewy bodies disease (DLB), Alzheimer\'s disease (AD), and attention deficit hyperactivity disorder (ADHD).
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